Production (Stage)
Bolt Biotherapeutics, Inc.
BOLT
$5.64
-$0.13-2.25%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 30.72% | -5.01% | 28.40% | -96.05% | 39.61% |
| Total Depreciation and Amortization | -6.34% | -3.18% | -3.72% | -0.22% | -1.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -63.66% | 68.84% | -52.23% | 38.20% | 25.12% |
| Change in Net Operating Assets | -196.91% | -106.92% | -132.58% | 121.02% | -648.41% |
| Cash from Operations | 7.38% | -3.32% | 13.48% | 3.64% | -17.43% |
| Capital Expenditure | -- | 100.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 11.09% | -28.18% | -5.40% | 76.45% | -35.49% |
| Cash from Investing | 18.96% | -28.63% | -4.80% | 76.45% | -35.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -100.00% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 154.68% | -168.38% | 63.51% | 129.63% | -496.85% |